You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Girentuximab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Girentuximab?

Girentuximab is an investigational drug.

There have been 6 clinical trials for Girentuximab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2017.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Kidney Neoplasms. The leading clinical trial sponsors are Radboud University, Wilex, and Abramson Cancer Center of the University of Pennsylvania.

There are twelve US patents protecting this investigational drug and three hundred and twenty-two international patents.

Recent Clinical Trials for Girentuximab
TitleSponsorPhase
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal OriginKWFPhase 1/Phase 2
Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal OriginRadboud UniversityPhase 1/Phase 2
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CTWilexPhase 3

See all Girentuximab clinical trials

Clinical Trial Summary for Girentuximab

Top disease conditions for Girentuximab
Top clinical trial sponsors for Girentuximab

See all Girentuximab clinical trials

US Patents for Girentuximab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Girentuximab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Girentuximab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Girentuximab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Girentuximab   Start Trial Classifying a cancer disease using CAIX expression Wilex AG (Munchen, DE)   Start Trial
Girentuximab   Start Trial Curcuphenol compounds for increasing MHC-I expression CAVA HEALTHCARE INC. (CA)   Start Trial
Girentuximab   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Girentuximab

Drugname Country Document Number Estimated Expiration Related US Patent
Girentuximab Canada CA2900764 2033-02-08   Start Trial
Girentuximab European Patent Office EP2954056 2033-02-08   Start Trial
Girentuximab Hong Kong HK1218930 2033-02-08   Start Trial
Girentuximab Japan JP2016509014 2033-02-08   Start Trial
Girentuximab World Intellectual Property Organization (WIPO) WO2014124326 2033-02-08   Start Trial
Girentuximab Australia AU2013220749 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.